January 14th, 2022 | 12:17 CET
Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus
Table of contents:
"[...] We believe that these findings could be of great benefit in protecting at-risk patients. [...]" David Elsley, CEO, Cardiol Therapeutics
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Vaccine manufacturers under pressure
Vaccine manufacturers are among the companies with the most executed orders on Tradegate on Friday. BioNTech currently leads the way with over 3,800 trades, ahead of Novavax with over 2,300 trades. BioNTech is trading at EUR 170.55, down 3.89%, and Novavax is currently trading at EUR 93.01, down 5.19%. Only Valneva can hold at the level of the previous day at EUR 16.30.
Forbes: natural active ingredient against Covid-19
Researchers from Oregon State University have found that ingredients of cannabis prevent from infection with the virus that causes Covid-19 by blocking its entry into cells, according to a study. The researchers found that cannabigerolic acid and cannabidiolic acid can bind to the spike protein of SARS-CoV-2, the virus that causes Covid-19. "Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2,," the researchers wrote in their summary of the study.
Researchers at the biotech company Cardiol Therapeutics are also betting on the effects of cannabis' natural ingredients for heart disease. The prospects for success seem compelling, as the company successfully completed a USD 50 million financing in November 2021. The stock market value was most recently CAD 131 million, far from the billion-dollar valuations of BioNTech, Novavax and Valneva. The experts at GBC Research recommend the share as a buy and name a price target of CAD 17.49. At a price of EUR 1.55, the share is currently up 4.03% and has a high price potential based on the analysts' opinion.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.